 |
63 Diseases |  |
25 Trials |
|
25 Trials |  |
493 News |  |
| «1234567 |
- ||||| fosaprepitant / Generic mfg.
New P2 trial, Metastases: Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy (clinicaltrials.gov) - Apr 3, 2015
P2, N=150, Not yet recruiting, Sponsor: Ajeet Gajra
- Enrollment closed, Trial primary completion date: Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy (clinicaltrials.gov) - Mar 31, 2015
P=N/A, N=42, Active, not recruiting, Sponsor: Philip Philip
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Sep 2015
- ||| dexamethasone / Generic mfg., cisplatin / Generic mfg., fosaprepitant / Generic mfg.
Enrollment closed: Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors (clinicaltrials.gov) - Mar 18, 2015
P2, N=64, Active, not recruiting, Sponsor: Lawrence Einhorn
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Sep 2015 Recruiting --> Active, not recruiting
- fosaprepitant / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting (clinicaltrials.gov) - Mar 10, 2015
P4, N=20, Terminated, Sponsor: Gynecologic Oncology Associates
Recruiting --> Active, not recruiting N=75 --> 20 | Recruiting --> Terminated | Trial primary completion date: Sep 2014 --> Mar 2015
- || dexamethasone / Generic mfg., cisplatin / Generic mfg., fosaprepitant / Generic mfg.
Trial primary completion date: Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors (clinicaltrials.gov) - Feb 27, 2015
P2, N=64, Recruiting, Sponsor: Hoosier Cancer Research Network
N=75 --> 20 | Recruiting --> Terminated | Trial primary completion date: Sep 2014 --> Mar 2015 Trial primary completion date: Jan 2015 --> Jun 2015
- fosaprepitant / Generic mfg.
Trial primary completion date: Fosaprepitant in Patients Receiving Ifosfamide-based Regimen (clinicaltrials.gov) - Feb 5, 2015
P=N/A, N=40, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jan 2015 --> Jun 2015 Trial primary completion date: May 2015 --> May 2016
- |||| cisplatin / Generic mfg., cyclophosphamide / Generic mfg.
Enrollment open, Trial primary completion date: Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy (clinicaltrials.gov) - Jan 12, 2015
P2, N=315, Recruiting, Sponsor: Acacia Pharma Ltd
Trial primary completion date: May 2015 --> May 2016 Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2014 --> Jan 2015
- || fosaprepitant / Generic mfg.
Trial primary completion date: Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029) (clinicaltrials.gov) - Dec 19, 2014
P2b, N=227, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2014 --> Jan 2015 Trial primary completion date: Mar 2017 --> Jul 2016
- |||| dexamethasone / Generic mfg., cisplatin / Generic mfg., fosaprepitant / Generic mfg.
Trial primary completion date: GAND-emesis: Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin (clinicaltrials.gov) - Dec 17, 2014
P3, N=230, Recruiting, Sponsor: Odense University Hospital
Trial primary completion date: Mar 2017 --> Jul 2016 Trial primary completion date: Oct 2014 --> Jun 2015
- ||||||| fosaprepitant / Generic mfg.
Trial completion: Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031) (clinicaltrials.gov) - Nov 18, 2014
P3, N=1015, Completed, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Oct 2014 --> Jun 2015 Active, not recruiting --> Completed
- ||||| fosaprepitant / Generic mfg.
Enrollment closed: Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031) (clinicaltrials.gov) - Nov 11, 2014
P3, N=1015, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | fosaprepitant / Generic mfg.
Trial termination: Fosaprepitant (MK-0517, EMEND (clinicaltrials.gov) - Oct 30, 2014
P2, N=111, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Completed --> Terminated; Low enrollment
- | fosaprepitant / Generic mfg.
Trial completion: Examine the Efficacy and Safety of a Single Dose of Intravenous MK-0517 (EUDRACT) - Aug 30, 2014
P3, N=990, Completed, Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Completed --> Terminated; Low enrollment Ongoing --> Completed
- |||||| olanzapine / Generic mfg.
Enrollment open, Trial initiation date, CINV: Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy (clinicaltrials.gov) - Aug 7, 2014
P3, N=372, Recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Ongoing --> Completed Not yet recruiting --> Recruiting | Initiation date: May 2014 --> Aug 2014
- Enrollment change, Trial termination, Trial primary completion date, Surgery, Metastases: A Pilot Study of Induction Chemotherapy Followed by Surgery for Locally Advanced Resectable Head and Neck Cancer (clinicaltrials.gov) - Jul 24, 2014
P0, N=4, Terminated, Sponsor: Southern Illinois University
Not yet recruiting --> Recruiting | Initiation date: May 2014 --> Aug 2014 N=10 --> 4 | Recruiting --> Terminated | Trial primary completion date: Dec 2014 --> Jul 2014; lack of enrollment
- fosaprepitant / Generic mfg., Sancuso (granisetron) / Solasia
Trial primary completion date: Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy (clinicaltrials.gov) - Jun 1, 2014
P=N/A, N=40, Recruiting, Sponsor: University of Southern California
N=10 --> 4 | Recruiting --> Terminated | Trial primary completion date: Dec 2014 --> Jul 2014; lack of enrollment Trial primary completion date: Sep 2014 --> Sep 2015
- || olanzapine / Generic mfg.
New P3 trial, CINV: Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy (clinicaltrials.gov) - Apr 15, 2014
P3, N=372, Not yet recruiting, Sponsor: Alliance for Clinical Trials in Oncology
- |||||||||| Sustol (granisetron ER) / Heron Therapeutics
New P3 trial: A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC (clinicaltrials.gov) - Apr 6, 2014
P3, N=1000, Recruiting, Sponsor: Heron Therapeutics
- |||||| Sustol (granisetron ER) / Heron Therapeutics
Enrollment open: A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC (clinicaltrials.gov) - Apr 2, 2014
P3, N=1000, Recruiting, Sponsor: Heron Therapeutics
Trial primary completion date: Sep 2014 --> Sep 2015 Not yet recruiting --> Recruiting
- fosaprepitant / Generic mfg.
Trial termination: A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134) (clinicaltrials.gov) - Feb 3, 2014
P1, N=92, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Recruiting --> Terminated; Study terminated early prior to completing targeted enrollment of participants <6 months of age due to recruitment challenges.
- fosaprepitant / Generic mfg.
Enrollment closed: Fosaprepitant in Patients Receiving Ifosfamide-based Regimen (clinicaltrials.gov) - Jan 30, 2014
P=N/A, N=40, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Terminated; Study terminated early prior to completing targeted enrollment of participants <6 months of age due to recruitment challenges. Recruiting --> Active, not recruiting
- |||| fosaprepitant / Generic mfg.
Enrollment open: Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting (clinicaltrials.gov) - Jan 23, 2014
P4, N=75, Recruiting, Sponsor: Gynecologic Oncology Associates
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- |||| fosaprepitant / Generic mfg.
Trial completion: Fosaprepitant (MK-0517, EMEND (clinicaltrials.gov) - Jan 22, 2014
P2, N=111, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Recruiting Recruiting --> Completed
- || fosaprepitant / Generic mfg.
Enrollment change: A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012) (clinicaltrials.gov) - Oct 20, 2013
P1, N=188, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed N=76 --> 188
- | fosaprepitant / Generic mfg.
Metastases: Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma (clinicaltrials.gov) - Oct 7, 2013
P2b, N=22, Recruiting, Sponsor: St. Louis University
N=76 --> 188 Not yet recruiting --> Recruiting
- | fosaprepitant / Generic mfg.
New P2b trial, Metastases: Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma (clinicaltrials.gov) - Jun 6, 2013
P2b, N=22, Recruiting, Sponsor: St. Louis University
- ||||| cisplatin / Generic mfg., cyclophosphamide / Generic mfg.
New P2 trial: Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy (clinicaltrials.gov) - May 16, 2013
P2, N=315, Not yet recruiting, Sponsor: Acacia Pharma Ltd
- fosaprepitant / Generic mfg.
Trial termination: Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy (clinicaltrials.gov) - May 15, 2013
P1/2, N=34, Terminated, Sponsor: OHSU Knight Cancer Institute
Not yet recruiting --> Recruiting Recruiting --> Terminated; Drug contract timelines and inadequate enrollment
- fosaprepitant / Generic mfg.
Trial termination: Fosaprepitant for Breakthrough Chemotherapy Induced Nausea and Vomiting (clinicaltrials.gov) - Apr 29, 2013
P2, N=34, Terminated, Sponsor: OHSU Knight Cancer Institute
Recruiting --> Terminated; Drug contract timelines and inadequate enrollment Recruiting --> Terminated
- cisplatin / Generic mfg., fosaprepitant / Generic mfg.
Trial termination, Metastases: Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy (clinicaltrials.gov) - Apr 16, 2013
P2, N=6, Terminated, Sponsor: University of Washington
Recruiting --> Terminated Completed --> Terminated; Study stopped due to lack of efficacy in first 6 patients
- cisplatin / Generic mfg., fosaprepitant / Generic mfg.
Enrollment change, Metastases: Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy (clinicaltrials.gov) - Apr 16, 2013
P2, N=6, Terminated, Sponsor: University of Washington
Completed --> Terminated; Study stopped due to lack of efficacy in first 6 patients N=45 --> 6
- ||| fosaprepitant / Generic mfg.
Trial completion, Surgery: A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148) (clinicaltrials.gov) - Mar 31, 2013
P1, N=98, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=45 --> 6 Recruiting --> Completed
- |||| dexamethasone / Generic mfg., cisplatin / Generic mfg., fosaprepitant / Generic mfg.
Enrollment open: Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors (clinicaltrials.gov) - Jan 8, 2013
P2, N=64, Recruiting, Sponsor: Hoosier Oncology Group
Recruiting --> Completed Not yet recruiting --> Recruiting
- | fosaprepitant / Generic mfg.
Enrollment change: Examine the Efficacy and Safety of a Single Dose of Intravenous MK-0517 (EUDRACT) - Dec 4, 2012
P3, N=990, Ongoing, Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.`Merck Corporation, Inc.
Not yet recruiting --> Recruiting N=50 --> 990
- ||||| dexamethasone / Generic mfg., cisplatin / Generic mfg., fosaprepitant / Generic mfg.
New P2 trial: Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors (clinicaltrials.gov) - Nov 27, 2012
P2, N=64, Recruiting, Sponsor: Hoosier Oncology Group
- |||||| fosaprepitant / Generic mfg.
New P2b trial: Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029) (clinicaltrials.gov) - Sep 30, 2012
P2b, N=256, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- |||||| fosaprepitant / Generic mfg.
Enrollment open: Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031) (clinicaltrials.gov) - Sep 30, 2012
P3, N=990, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=50 --> 990 Not yet recruiting --> Recruiting
- fosaprepitant / Generic mfg., Sancuso (granisetron) / Solasia
Enrollment open: Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy (clinicaltrials.gov) - Sep 9, 2012
P=N/A, N=39, Recruiting, Sponsor: University of Southern California
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Trial initiation date: Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy (clinicaltrials.gov) - Jul 23, 2012
P=N/A, N=42, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Not yet recruiting --> Recruiting Initiation date: Jan 2012 --> Jun 2012
- Enrollment open: Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy (clinicaltrials.gov) - Jul 23, 2012
P=N/A, N=42, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Initiation date: Jan 2012 --> Jun 2012 Not yet recruiting --> Recruiting
- || fosaprepitant / Generic mfg.
New P3 trial: Examine the Efficacy and Safety of a Single Dose of Intravenous MK-0517 (EUDRACT) - May 24, 2012
P3, N=990, Ongoing, Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.`Merck Corporation, Inc.
- |||||||||| fosaprepitant / Generic mfg.
New P3 trial: Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031) (clinicaltrials.gov) - May 7, 2012
P3, N=990, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- fosaprepitant / Generic mfg.
Enrollment change: Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183) (clinicaltrials.gov) - Nov 1, 2011
P1, N=16, Completed, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting N=24 --> 16
- ||||| fosaprepitant / Generic mfg.
New P4 trial: Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting (clinicaltrials.gov) - Sep 8, 2011
P4, N=75, Recruiting, Sponsor: Gynecologic Oncology Associates